Company Profiles

driven by the PitchBook Platform

Artios Pharma

Description

Developer of deoxyribonucleic acid (DNA) Damage Response (DDR) cancer therapies. The company provides cancer treatment therapies through deoxyribonucleic acid damage response (DDR) pathways to allow mutations to their deoxyribonucleic acid (DNA) so that they can evolve.

2015

Founded

PRIVATE

Status

1-10

Employees

Series A

Latest Deal Type

$32.9M

Latest Deal Amount

$32.9M

Total Amount Raised

Description

Developer of deoxyribonucleic acid (DNA) Damage Response (DDR) cancer therapies. The company provides cancer treatment therapies through deoxyribonucleic acid damage response (DDR) pathways to allow mutations to their deoxyribonucleic acid (DNA) so that they can evolve.

Website:

www.artiospharma.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

Babraham Hall (B 301) Babraham Research Campus Cambridge CB22 3ATEngland +44 (0)12 2380 4180
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Artios Pharma's full profile, request a free trial.

Artios Pharma Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Artios Pharma Investors (7)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AbbVie VenturesCorporate Venture CapitalMinority000 0000000 0000
Arix BioscienceVenture CapitalMinority000 0000000 0000
Babraham Bioscience TechnologiesAccelerator/IncubatorMinority000 0000000 0000
Merck VenturesCorporate Venture CapitalMinority000 0000000 0000
Sixth Element CapitalVenture CapitalMinority000 0000000 0000
AbbVie Ventures Corporate Venture Capital
Arix Bioscience Venture Capital
Babraham Bioscience Technologies Accelerator/Incubator
Merck Ventures Corporate Venture Capital
Sixth Element Capital Venture Capital

Artios Pharma Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Niall Martin Ph.DChief Executive Officer & Board Member
Andrew MunceyChief Financial Officer & Company Secretary
Nick Staples Ph.DChief Business Officer
Simon Boulton Ph.DVice President, Scientific Strategy
Peter Harris MDChief Medical Officer
Niall Martin Ph.D Chief Executive Officer & Board Member
Andrew Muncey Chief Financial Officer & Company Secretary
Nick Staples Ph.D Chief Business Officer
Simon Boulton Ph.D Vice President, Scientific Strategy
Peter Harris MD Chief Medical Officer

Artios Pharma Board Members (10)

NameRepresentingRoleSinceContact
Info
Alicia Irurzun-LafitteSelfBoard Observer000 0000
Alicia Irurzun-LafitteMerck VenturesPrincipal000 0000
Bobby Soni Ph.DTouchstone InnovationsDirector of Healthcare Investments000 0000
Hakan Goker Ph.DMerck VenturesSenior Investment Director000 0000
Hamish Cameron MDSV Health InvestorsOperating Partner000 0000
Alicia Irurzun-Lafitte Board Observer Self
Alicia Irurzun-Lafitte Principal Merck Ventures
Bobby Soni Ph.D Director of Healthcare Investments Touchstone Innovations
Hakan Goker Ph.D Senior Investment Director Merck Ventures
Hamish Cameron MD Operating Partner SV Health Investors
Request full access to PitchBook